Niagen Bioscience - 10-Q quarterly report FY2015 Q3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 3, 2015

Commission File Number: 000-53290

CHROMADEX CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Delaware		26-2940963
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
10005 Muirlands Blvd. Suite G, Irvine, California		92618
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code: (949) 419-0288

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes X No

Indicate by check mark whether the registrant is a large accelerated filer, accelerated filer, non-accelerated filer or smaller reporting company. See definition of “large accelerated filer, accelerated filer and smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ___		Accelerated filer X
Non-accelerated filer ___ (Do not check if smaller reporting company)		Smaller reporting company ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ___ No X

Number of shares of common stock of the registrant: 109,114,247 outstanding as of November 11, 2015.

CHROMADEX CORPORATION

2015 QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION (UNAUDITED)

	ITEM 1. FINANCIAL STATEMENTS:

		Condensed Consolidated Balance Sheets as of October 3, 2015 (Unaudited) and January 3, 2015	1
		Condensed Consolidated Statements of Operations for the three months ended October 3, 2015 and September 27, 2014 (Unaudited)	2
		Condensed Consolidated Statements of Operations for the nine months ended October 3, 2015 and September 27, 2014 (Unaudited)	3
		Condensed Consolidated Statements of Stockholders Equity for the nine months ended October 3, 2015 (Unaudited)	4
		Condensed Consolidated Statements of Cash Flows for the nine months ended October 3, 2015 and September 27, 2014 (Unaudited)	5
		Notes to Condensed Consolidated Financial Statements (Unaudited)	6

	ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		18
	ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK		24
	ITEM 4. CONTROLS AND PROCEDURES		25


PART II – OTHER INFORMATION

	ITEM 1. LEGAL PROCEEDINGS		25
	ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS		25
	ITEM 3. DEFAULTS UPON SENIOR SECURITIES		25
	ITEM 4. MINE SAFETY DISCLOSURES		25
	ITEM 5. OTHER INFORMATION		25
	ITEM 6. EXHIBITS		26

	SIGNATURES		27

-i-

Table of Contents

PART I – FINANCIAL INFORMATION (UNAUDITED)

ITEM 1. FINANCIAL STATEMENTS

ChromaDex Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

October 3, 2015 and January 3, 2015

	October 3, 2015			January 3, 2015
	(Unaudited)
Assets

Current Assets
Cash	$	4,708,642		$	3,964,750
Trade receivables, less allowance for doubtful accounts and returns
October 3, 2015 $43,000; January 3, 2015 $38,000		3,784,541			1,906,709
Inventories		4,163,628			3,734,341
Prepaid expenses and other assets		377,469			292,891
Total current assets		13,034,280			9,898,691

Leasehold Improvements and Equipment, net		1,581,961			1,264,660
Deposits		59,040			57,435
Intangible assets, net		371,325			296,061

Total assets	$	15,046,606		$	11,516,847

Liabilities and Stockholders' Equity

Current Liabilities
Accounts payable	$	3,560,569		$	3,451,608
Accrued expenses		1,215,166			853,685
Current maturities of loan payable		598,837			223,358
Current maturities of capital lease obligations		216,551			148,278
Customer deposits and other		236,828			234,435
Deferred rent, current		52,914			69,456
Total current liabilities		5,880,865			4,980,820

Loan payable, less current maturities, net		4,226,414			1,977,113
Capital lease obligations, less current maturities		500,128			423,015
Deferred rent, less current		103,461			137,508

Total liabilities		10,710,868			7,518,456

Commitments and contingencies

Stockholders' Equity
Common stock, $.001 par value; authorized 150,000,000 shares;
issued and outstanding October 3, 2015 106,319,606 and
January 3, 2015 105,271,058 shares		106,320			105,271
Additional paid-in capital		45,098,163			43,417,442
Accumulated deficit		(40,868,745	)		(39,524,322	)
Total stockholders' equity		4,335,738			3,998,391

Total liabilities and stockholders' equity	$	15,046,606		$	11,516,847

See Notes to Condensed Consolidated Financial Statements.

-1-

Table of Contents

ChromaDex Corporation and Subsidiaries
Condensed Consolidated Statements of Operations (Unaudited)
For the Three Month Periods Ended October 3, 2015 and September 27, 2014
	October 3, 2015			September 27, 2014

Sales, net	$	6,287,309		$	4,139,710
Cost of sales		3,805,679			2,616,764

Gross profit		2,481,630			1,522,946

Operating expenses:
Sales and marketing		550,878			518,662
General and administrative		1,753,622			1,651,718
Operating expenses		2,304,500			2,170,380

Operating income (loss)		177,130			(647,434	)

Nonoperating income (expense):
Interest income		976			230
Interest expense		(181,822	)		(12,449	)
Nonoperating expenses		(180,846	)		(12,219	)

Net loss	$	(3,716	)	$	(659,653	)

Basic and Diluted loss per common share	$	(0.00	)	$	(0.01	)

Basic and Diluted weighted average common shares outstanding		107,442,916			106,610,400

See Notes to Condensed Consolidated Financial Statements.

-2-

Table of Contents

ChromaDex Corporation and Subsidiaries
Condensed Consolidated Statements of Operations (Unaudited)
For the Nine Month Periods Ended October 3, 2015 and September 27, 2014
	October 3, 2015			September 27, 2014

Sales, net	$	17,649,660		$	11,070,002
Cost of sales		10,769,714			7,163,282

Gross profit		6,879,946			3,906,720

Operating expenses:
Sales and marketing		1,776,403			1,554,777
General and administrative		6,016,557			6,458,027
Loss from investment in affiliate		-			21,543
Operating expenses		7,792,960			8,034,347

Operating loss		(913,014	)		(4,127,627	)

Nonoperating income (expense):
Interest income		2,339			1,175
Interest expense		(433,748	)		(34,359	)
Nonoperating expenses		(431,409	)		(33,184	)

Net loss	$	(1,344,423	)	$	(4,160,811	)

Basic and Diluted loss per common share	$	(0.01	)	$	(0.04	)

Basic and Diluted weighted average common shares outstanding		107,350,469			106,290,782

See Notes to Condensed Consolidated Financial Statements.

-3-

Table of Contents

ChromaDex Corporation and Subsidiaries
Condensed Consolidated Statement of Stockholders' Equity (Unaudited)
For the Nine Month Period Ended October 3, 2015
					Additional						Total
	Common Stock				Paid-in			Accumulated			Stockholders'
	Shares		Amount		Capital			Deficit			Equity
Balance, January 3, 2015		105,271,058	$	105,271	$	43,417,442		$	(39,524,322	)	$	3,998,391

Share-based compensation		210,000		210		715,699			-			715,909

Vested restricted stock		506,000		506		(506	)		-			-

Net loss		-		-		-			(1,025,515	)		(1,025,515	)

Balance, April 4, 2015		105,987,058		105,987		44,132,635			(40,549,837	)		3,688,785

Exercise of stock options		22,745		23		15,578			-			15,601

Share-based compensation		125,000		125		507,143			-			507,268

Vested restricted stock		156,000		156		(156	)		-			-

Net loss		-		-		-			(315,192	)		(315,192	)

Balance, July 4, 2015		106,290,803		106,291		44,655,200			(40,865,029	)		3,896,462

Exercise of stock options		12,803		13		9,652			-			9,665

Share-based compensation		-		-		433,327			-			433,327

Vested restricted stock		16,000		16		(16	)		-			-

Net loss		-		-		-			(3,716	)		(3,716	)

Balance, October 3, 2015		106,319,606	$	106,320	$	45,098,163		$	(40,868,745	)	$	4,335,738

See Notes to Condensed Consolidated Financial Statements.

-4-

Table of Contents

ChromaDex Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
For the Nine Month Periods Ended October 3, 2015 and September 27, 2014
	October 3, 2015			September 27, 2014

Cash Flows From Operating Activities
Net loss	$	(1,344,423	)	$	(4,160,811	)
Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation of leasehold improvements and equipment		209,754			161,712
Amortization of intangibles		32,236			24,826
Share-based compensation expense		1,656,504			2,467,720
Allowance for doubtful trade receivables		5,429			24,190
Gain on exchange of equipment		-			(17,301	)
Loss from disposal of equipment		19,643			-
Loss from investment in affiliate		-			21,543
Non-cash financing costs		139,780			-
Changes in operating assets and liabilities:
Trade receivables		(1,883,261	)		(1,714,035	)
Other receivable		-			215,000
Inventories		(429,287	)		(81,961	)
Prepaid expenses and other assets		(86,183	)		(87,068	)
Accounts payable		108,961			967,229
Accrued expenses		361,481			201,147
Customer deposits and other		2,393			(320,127	)
Deferred rent		(50,589	)		(36,732	)
Net cash used in operating activities		(1,257,562	)		(2,334,668	)

Cash Flows From Investing Activities
Purchases of leasehold improvements and equipment		(242,765	)		(53,428	)
Purchases of intangible assets		(107,500	)		(90,000	)
Proceeds from sale of equipment		-			1,356
Proceeds from investment in affiliate		-			1,092,500
Net cash provided by (used in) investing activities		(350,265	)		950,428

Cash Flows From Financing Activities
Proceeds from exercise of stock options		25,266			449,158
Proceeds from loan payable		2,500,000			-
Payment of debt issuance cost		(15,000	)		-
Principal payments on capital leases		(158,547	)		(122,496	)
Net cash provided by financing activities		2,351,719			326,662

Net increase (decrease) in cash		743,892			(1,057,578	)

Cash Beginning of Period		3,964,750			2,261,336

Cash Ending of Period	$	4,708,642		$	1,203,758

Supplemental Disclosures of Cash Flow Information
Cash payments for interest	$	293,968		$	34,359

Supplemental Schedule of Noncash Investing Activity
Capital lease obligation incurred for purchases of equipment	$	303,933		$	322,802
Retirement of fully depreciated equipment - cost	$	8,181		$	56,110
Retirement of fully depreciated equipment - accumulated depreciation	$	(8,181	)	$	(56,110	)

Supplemental Schedule of Noncash Operating Activity
Stock issued to settle outstanding payable balance	$	-		$	137,494

Supplemental Schedule of Noncash Share-based Compensation
Changes in prepaid expenses associated with share-based compensation	$	-		$	55,631

See Notes to Condensed Consolidated Financial Statements.

-5-

Table of Contents

Note 1. Interim Financial Statements

The accompanying financial statements of ChromaDex Corporation (the “Company”) and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. include all adjustments, consisting of normal recurring adjustments and accruals, that, in the opinion of the management of the Company, are necessary for a fair presentation of the Company’s financial position as of October 3, 2015 and results of operations and cash flows for the three and nine months ended October 3, 2015 and September 27, 2014. These unaudited interim financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended January 3, 2015 appearing in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2015. Operating results for the nine months ended October 3, 2015 are not necessarily indicative of the results to be achieved for the full year ending on January 2, 2016. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

The balance sheet at January 3, 2015 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.

Note 2. Nature of Business and Liquidity

Nature of business: The Company is a natural products company that leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to the Company’s ingredient technologies unit, the Company also has business units focused on natural product fine chemicals (known as “phytochemicals”), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of the Company’s relationships with leading universities and research institutions, the Company is able to discover and license early stage, Intellectual Property-backed ingredient technologies. The Company then utilizes the Company’s in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. The Company’s ingredient portfolio is backed with clinical and scientific research, as well as extensive Intellectual Property protection.

Liquidity: The Company has incurred a loss from operations of approximately $913,000 and a net loss of approximately $1,344,000 for the nine-month period ended October 3, 2015. As of October 3, 2015, the cash and cash equivalents totaled approximately $4,709,000. Subsequent to the nine-month period ended October 3, 2015, the Company entered into Securities Purchase Agreements (the “SPAs”) with certain existing stockholders to raise $2,000,000 in a registered direct offering. Pursuant to the SPAs, the Company sold a total of 200,000 units (the “Units”) at a purchase price of $10.00 per Unit, with each Unit consisting of eight shares of the Company’s common stock and a warrant to purchase four shares of common stock with an exercise price of $1.50 and a term of 3 years.

With the capital raise described above, we anticipate that our current cash and cash equivalents on hand and cash generated from operations will be sufficient meet our projected operating plans through at least December 31, 2016. We may, however, require additional funds, either through additional equity or debt financings or collaborative agreements or from other sources. We have no commitments to obtain such additional financing, and we may not be able to obtain any such additional financing on terms favorable to us, or at all. If adequate financing is not available, the Company will further delay, postpone or terminate product and service expansion and curtail certain selling, general and administrative operations. The inability to raise additional financing may have a material adverse effect on the future performance of the Company.

-6-

Table of Contents

Note 3. Significant Accounting Policies

Basis of presentation: The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company’s fiscal year ends on the Saturday closest to December 31. Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date. The fiscal year 2014 ended on January 3, 2015 consisted of 53 weeks. The fiscal year 2015 ending on January 2, 2016 will include the normal 52 weeks.

Changes in accounting principle: In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs have not changed.

The Company early adopted the amendments in this ASU effective as of April 4, 2015. As of October 3, 2015 and January 3, 2015, the Company had unamortized debt issuance costs of $75,264 and $91,361, respectively. The Company had previously presented the debt issuance costs as other noncurrent assets in its consolidated balance sheet as of January 3, 2015 in the Company’s Annual Report on Form 10-K filed with the Commission on March 19, 2015. The early adoption has resulted in adjustments to the Company’s consolidated balance sheet as of January 3, 2015, by reclassifying the debt issuance costs as a direct deduction from the carrying amount of the debt liability. Below are the effects of the change on the consolidated balance sheet as of January 3, 2015.

ChromaDex Corporation and Subsidiaries
Condensed Consolidated Balance Sheet
January 3, 2015	Previously					As
	Reported		Adjustments			Adjusted
Assets

Current Assets	$	9,898,691	$	-		$	9,898,691
Leasehold Improvements and Equipment, net		1,264,660		-			1,264,660
Other Noncurrent Assets		444,857		(91,361	)		353,496
Total assets	$	11,608,208	$	(91,361	)	$	11,516,847

Liabilities and Stockholders' Equity

Current Liabilities	$	4,980,820	$	-		$	4,980,820
Loan payable, less current maturities, net		2,068,474		(91,361	)		1,977,113
Capital lease obligations, less current maturities		423,015		-			423,015
Deferred rent, less current		137,508		-			137,508
Total liabilities		7,609,817		(91,361	)		7,518,456

Total stockholders' equity		3,998,391		-			3,998,391

Total liabilities and stockholders' equity	$	11,608,208	$	(91,361	)	$	11,516,847

-7-

Table of Contents

Inventories: Inventories are comprised of raw materials, work-in-process and finished goods. They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market. Labor and overhead has been added to inventory that was manufactured or characterized by the Company. The amounts of major classes of inventory as of October 3, 2015 and January 3, 2015 are as follows:

	October 3, 2015		January 3, 2015
Natural product fine chemicals	$	1,695,326	$	1,760,305
Bulk ingredients		3,163,302		2,298,036
		4,858,628		4,058,341
Less valuation allowance		695,000		324,000
	$	4,163,628	$	3,734,341

Note 4. Loss Per Share Applicable to Common Stockholders

The following table sets forth the computations of loss per share amounts applicable to common stockholders for the three and nine months ended October 3, 2015 and September 27, 2014:

	Three Months Ended						Nine Months Ended
	Oct. 3, 2015			Sept. 27, 2014			Oct. 3, 2015			Sept. 27, 2014

Net loss	$	(3,716	)	$	(659,653	)	$	(1,344,423	)	$	(4,160,811	)

Basic and diluted loss per common share	$	(0.00	)	$	(0.01	)	$	(0.01	)	$	(0.04	)

Weighted average common shares outstanding (1):		107,442,916			106,610,400			107,350,469			106,290,782

Potentially dilutive securities (2):
Stock options		15,839,603			13,890,766			15,839,603			13,890,766
Warrants		469,020			-			469,020			-
Convertible Debt		773,395			-			773,395			-

(1) Includes 1,132,241 and 1,676,175 weighted average nonvested shares of restricted stock for the three months ended October 3, 2015 and September 27, 2014, respectively, and 1,305,605 and 1,606,380 weighted average nonvested shares of restricted stock for the nine months ended October 3, 2015 and September 27, 2014, respectively, which are participating securities that feature voting and dividend rights.

(2) Excluded from the computation of loss per share as their impact is antidilutive.

-8-

Table of Contents

Note 5. Leasehold Improvements and Equipment

Leasehold improvements and equipment consisted of the following:

	October 3, 2015		January 3, 2015
Laboratory equipment	$	3,577,132	$	3,151,748
Leasehold improvements		513,453		495,240
Computer equipment		379,806		329,737
Furniture and fixtures		15,678		13,039
Office equipment		21,547		7,877
Construction in progress		21,561		68,141
		4,529,177		4,065,782
Less accumulated depreciation		2,947,216		2,801,122
	$	1,581,961	$	1,264,660

Depreciation expense on leasehold improvements and equipment included in the consolidated statement of operations for the nine months ended October 3, 2015 and September 27, 2014 was approximately $210,000 and $162,000, respectively.

Note 6. Loan Payable

On June 17, 2015, the Company and Hercules Technology II, L.P entered into Amendment No. 1 (the “Amendment”) to the Loan and Security Agreement entered into by the parties on September 29, 2014 (the “Agreement”). The terms of the Agreement provided the Company with access to a term loan of up to $5 million. The first $2.5 million of the term loan was funded at closing. The remaining $2.5 million of the term loan was to be drawn down in part or in full at our option at any time but no later than July 31, 2015. The first advance and second advance, if any, were to be repaid in equal monthly installments through the loan’s maturity on April 1, 2018, following an initial interest-only period that was to conclude on October 31, 2015.

Pursuant to the Amendment, the parties agreed that the interest only period shall be extended to March 31, 2016, provided however that if the Company’s consolidated revenue is equal to or greater than $11.5 million for the six months ending December 31, 2015, then the interest-only period shall be extended to June 30, 2016. The maturity date remains unchanged at April 1, 2018 and any remaining principal balance of the loan and all unpaid interest shall be due on the maturity date. The Amendment became effective on June 18, 2015 upon the funding of the full amount of the $2.5 million second advance and payment of a nonrenewable facility fee of $15,000 to the Agent.

The second advance of $2.5 million is treated as if the Company entered into a separate loan. The facility fee of $15,000 is treated as debt issuance costs and are being amortized as interest expense using the effective interest method over the term of the loan. There is also additional $93,750 end of term charge the Company will pay, which is 3.75% of the $2.5 million drawn. The end of term charge is being accrued as additional interest expense using the effective interest rate method over the term of the loan.

The Company determined that the amended terms of the first advance of $2.5 million on September 29, 2014 were not substantially different from the original terms. The Company therefore did not apply debt extinguishment treatment, but rather accounted for prospectively as yield adjustments, based on the revised terms.

-9-

Table of Contents

Loan payable as of October 3, 2015 consists of the following:

Principal amount payable for following years ending December
2015	$	-
2016		905,393
2017		1,945,650
2018		2,148,957
Total principal payments		5,000,000
Accrued end of term charge		49,551
Total loan payable		5,049,551
Less unamortized debt issuance costs and debt discount		224,300
Less current portion		598,837
Loan payable – long term	$	4,226,414

The total interest expenses related to the term loan, including cash interest payments, the amortizations of debt issuance costs and debt discount, and the accrual of the end of term charge were approximately $166,000 and $387,000 for the three and nine months ended October 3, 2015. For the three and nine months ended September 27, 2014, the Company did not have any interest expense related to loan payable as the Company did not have any outstanding balance.

Note 7. Share-Based Compensation

7A. Employee Share-Based Compensation

Stock Option Plans

Service Period Based Stock Options

The majority of options granted by the Company feature service conditions. Accordingly, these options vest ratably over specified periods of approximately 3 to 5 years following the date of grant.

The following table summarizes our stock option activity during the nine months ended October 3, 2015:

				Weighted Average
						Remaining		Aggregate
	Number of			Exercise		Contractual		Intrinsic
	Shares			Price		Term		Value
Outstanding at January 3, 2015		12,723,601		$	1.13		7.00
Options Granted		2,051,685			1.22		10.00
Options Classification from Employee to Non-Employee		(1,542,071	)		0.93
Options Exercised		(35,548	)		0.71
Options Forfeited		(150,586	)		1.16
Outstanding at October 3, 2015		13,047,081		$	1.17		6.64	$	2,389,000

Exercisable at October 3, 2015		9,793,365		$	1.16		5.84	$	2,061,000

The aggregate intrinsic values in the table above are based on the Company’s closing stock price of $1.25 on the last day of business for the period ended October 3, 2015.

Certain employees who were previously classified as employees under the share-based compensation plan have been reclassified to non-employees during the nine months ended October 3, 2015 as they became consultants. There was no impact on accounting as the options were fully vested.

-10-

Table of Contents

The fair value of the Company’s stock options was estimated at the date of grant using the Black-Scholes option pricing model. The table below outlines the weighted average assumptions for options granted to employees during the nine months ended October 3, 2015.

Nine Months Ended October 3, 2015
Expected volatility		76	%
Expected dividends		0.00	%
Expected term	5.7 years
Risk-free rate		1.71	%

The weighted average grant date fair value of options granted during the nine months ended October 3, 2015 was $0.75.

As of October 3, 2015, there was approximately $2,022,000 of total unrecognized compensation expense expected to be recognized over a weighted average period of 2.38 years.

Stock Award

On April 16, 2015, the Company awarded 125,000 shares of the Company’s common stock that were fully vested and non-forfeitable to Mark Germain, who resigned from the Board. These shares were granted as compensation for his services as a director of the Company through April 16, 2015. The fair value of the award, which amounted to approximately $154,000 was based on the trading price of the Company’s stock on the date of grant. The expense related to this stock award was immediately recognized.

Restricted Stock

Restricted stock awards granted by the Company to employees have vesting conditions that are unique to each award.

The following table summarizes activity of restricted stock awards granted to employees at October 3, 2015 and changes during the nine months then ended:

				Weighted Average
				Award-Date
	Shares			Fair Value
Unvested shares at January 3, 2015		1,590,000		$	1.18
Granted		-			-
Vested		(520,000	)		1.41
Forfeited		-			-
Unvested shares at October 3, 2015		1,070,000		$	1.07

Expected to Vest as of October 3, 2015		1,070,000		$	1.07

On February 25, 2015, Michael Brauser and Barry Honig, then members of the Company’s Board of Directors (the “Board”), resigned from the Board. In connection with these resignations, the Board authorized the immediate vesting, as of the date of the resignations, of 250,000 shares of unvested restricted stock held by Mr. Brauser and 250,000 shares of unvested restricted stock held by Mr. Honig. The expense for this vested restricted stock was recognized during the fiscal year ended January 3, 2015.

On April 16, 2015, Mark Germain, then a member of the Board, resigned from the Board. In connection with Mr. Germain’s resignation, the Board authorized the immediate vesting, as of the date of Mr. Germain’s resignation, of 10,000 shares of unvested restricted stock held by Mr. Germain. The expense for this vested restricted stock was recognized during the fiscal year ended January 3, 2015.

-11-

Table of Contents

On July 9, 2015, Glenn Halpryn, then a member of the Board, resigned from the Board. In connection with Mr. Halpryn’s resignation, the Board authorized the immediate vesting, as of the date of Mr. Halpryn’s resignation, of 10,000 shares of unvested restricted stock held by Mr. Halpryn. The expense for this vested restricted stock was recognized during the fiscal year ended January 3, 2015.

Employee Option, Stock and Restricted Stock Compensation

The Company recognized compensation expense of approximately $418,000 and $1,238,000 in general and administrative expenses in the statement of operations for the three and nine months ended October 3, 2015, respectively, and approximately $388,000 and $2,359,000 for the three and nine months ended September 27, 2014, respectively.

7B. Non-Employee Share-Based Compensation

Stock Option Plans

The following table summarizes activity of stock options granted to non-employees at October 3, 2015 and changes during the nine months then ended:

			Weighted Average
					Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
	Shares		Price		Term		Value
Outstanding at January 3, 2015		1,050,451	$	1.35		5.46
Options Granted		-		-
Options Classification from Employee to Non-Employee		1,542,071		0.93
Options Exercised		-		-
Options Forfeited		-		-
Outstanding at October 3, 2015		2,592,522	$	1.10		6.29	$	594,000

Exercisable at October 3, 2015		2,547,522	$	1.10		6.24	$	593,000

The aggregate intrinsic values in the table above are based on the Company’s closing stock price of $1.25 on the last day of business for the period ended October 3, 2015.

As of October 3, 2015, there was approximately $31,000 of total unrecognized compensation expense expected to be recognized over a weighted average period of approximately 11 months.

Stock and Restricted Stock Awards

Restricted stock awards granted by the Company to non-employees generally feature time vesting service conditions, specified in the respective service agreements. Restricted stock awards issued to non-employees are accounted for at current fair value through the vesting period. On January 27, 2015, the Company awarded 350,000 shares of the Company’s common stock to non-employees. 210,000 of these shares were treated as stock awards as the shares vested immediately on the date of award, and the remaining 140,000 shares, which were initially treated as unvested restricted stock, vested on May 28, 2015. The fair values of the awards, which totaled approximately $350,000, were measured based on the trading prices of the Company’s stock on the date of award and the date vested. The expense related to these stock awards were fully recognized during the nine-month period ended October 3, 2015.

In addition, 18,000 shares of restricted stock that were granted to a certain non-employee during the fiscal year ended January 3, 2015 became vested during the nine-month period ended October 3, 2015. The fair value of these vested restricted shares was approximately $22,000, which represents the market value of the Company’s common stock on respective vesting dates charged to expense.

-12-

Table of Contents

The following table summarizes activity of restricted stock awards issued to non-employees at October 3, 2015 and changes during the nine months then ended:

				Weighted Average
	Shares			Fair Value
Unvested shares at January 3, 2015		76,000		$	0.90
Granted		140,000			0.86
Vested		(158,000	)		1.21
Forfeited		-			-
Unvested shares expected to vest at October 3, 2015		58,000		$	1.25

As of October 3, 2015, there was approximately $73,000 of total unrecognized compensation expense related to the restricted stock award to a non-employee. That cost is expected to be recognized over a period of 2.4 years as of October 3, 2015.

Non-Employee Option, Stock and Restricted Stock Compensation

The Company recognized share-based compensation expense of approximately $15,000 and $418,000 in general and administrative expenses in the statement of operations for the three and nine months ended October 3, 2015 and approximately $43,000 and $109,000 for the three and nine months ended September 27, 2014, respectively.

Note 8. Business Segments

The Company has following three reportable segments.

·	Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients to the manufacturers of consumer products in various industries including the nutritional supplement, food and beverage and animal health industries.

·	Core standards, and contract services segment includes supply of phytochemical reference standards, which are small quantities of plant-based compounds typically used to research an array of potential attributes, reference materials, and related contract services.

·	Scientific and regulatory consulting segment which consist of providing scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.

The “Other” classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegment sales that require elimination. The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.

-13-

Table of Contents

			Core Standards and Contract Services segment		Scientific and Regulatory Consulting segment
Three months ended October 3, 2015	Ingredients segment
	Ingredients segment						Other			Total
Net sales	$	4,146,597	$	1,875,296	$	265,416	$	-		$	6,287,309
Cost of sales		2,157,183		1,533,402		115,094		-			3,805,679
Gross profit		1,989,414		341,894		150,322		-			2,481,630

Operating expenses:
Sales and marketing		259,874		287,901		3,103		-			550,878
General and administrative		-		-		-		1,753,622			1,753,622
Operating expenses		259,874		287,901		3,103		1,753,622			2,304,500

Operating income (loss)	$	1,729,540	$	53,993	$	147,219	$	(1,753,622	)	$	177,130

			Core Standards and Contract Services segment		Scientific and Regulatory Consulting segment
Three months ended September 27, 2014	Ingredients segment
	Ingredients segment						Other			Total
Net sales	$	2,031,250	$	1,814,622	$	293,838	$	-		$	4,139,710
Cost of sales		1,200,790		1,239,356		176,618		-			2,616,764
Gross profit		830,460		575,266		117,220		-			1,522,946

Operating expenses:
Sales and marketing		243,068		259,951		15,643		-			518,662
General and administrative		-		-		-		1,651,718			1,651,718
Operating expenses		243,068		259,951		15,643		1,651,718			2,170,380

Operating income (loss)	$	587,392	$	315,315	$	101,577	$	(1,651,718	)	$	(647,434	)

-14-

Table of Contents

Nine months ended October 3, 2015	Ingredients segment		Core Standards and Contract Services segment		Scientific and Regulatory Consulting segment		Other			Total
Net sales	$	10,238,574	$	6,546,816	$	864,270	$	-		$	17,649,660
Cost of sales		5,629,564		4,742,480		397,670		-			10,769,714
Gross profit		4,609,010		1,804,336		466,600		-			6,879,946

Operating expenses:
Sales and marketing		832,779		935,237		8,387		-			1,776,403
General and administrative		-		-		-		6,016,557			6,016,557
Operating expenses		832,779		935,237		8,387		6,016,557			7,792,960

Operating income (loss)	$	3,776,231	$	869,099	$	458,213	$	(6,016,557	)	$	(913,014	)

Nine months ended September 27, 2014	Ingredients segment		Core Standards and Contract Services segment		Scientific and Regulatory Consulting segment		Other			Total
Net sales	$	4,889,431	$	5,407,455	$	773,116	$	-		$	11,070,002
Cost of sales		2,962,505		3,728,521		472,256		-			7,163,282
Gross profit		1,926,926		1,678,934		300,860		-			3,906,720

Operating expenses:
Sales and marketing		793,414		694,523		66,840		-			1,554,777
General and administrative		-		-		-		6,458,027			6,458,027
Loss from investment in affiliate		-		-		-		21,543			21,543
Operating expenses		793,414		694,523		66,840		6,479,570			8,034,347

Operating income (loss)	$	1,133,512	$	984,411	$	234,020	$	(6,479,570	)	$	(4,127,627	)

-15-

Table of Contents

At October 3, 2015		Ingredients segment				Core Standards and Contract Services segment				Scientific and Regulatory Consulting segment				Other				Total
Total assets		$	6,527,861			$	3,042,917			$	110,284			$	5,365,544			$	15,046,606

At January 3, 2015		Ingredients segment				Core Standards and Contract Services segment				Scientific and Regulatory Consulting segment				Other				Total
Total assets		$	3,757,073			$	3,220,518			$	105,711			$	4,433,545			$	11,516,847

Disclosure of major customers

During the three and nine months ended October 3, 2015, Customer B in our ingredients segment accounted for 19.1% and 13.8%, respectively of the Company’s total sales. During the three and nine months ended September 27, 2014, Customer A in our ingredients segment accounted for 12.3% and 13.8%, respectively of the Company’s total sales.

Note 9. Commitments and Contingencies

Capitalized Lease Obligations

On January 31, 2015, the Company entered into a financing transaction to purchase laboratory equipment. Under the lease terms, the Company will make monthly lease payments, including interest, of approximately $7,000 for 48 months, for a total payment of approximately $356,000. The Company has recorded a capital lease of approximately $304,000. The equipment will be utilized in our core standards and contract services segment.

Inventory Purchase Obligations

On September 29, 2015, the Company entered into an agreement with W.R. Grace & Co. Conn. (“Grace”) pursuant to which the Company has agreed to purchase from Grace not less than approximately $6.1 million worth of nicotinamide riboside chloride (the “Required Volume”) at a fixed price per kilogram (the “Price per Kilogram”) between September 4, 2015 and December 31, 2015. So long as Grace makes available for sale to the Company the Required Volume prior to December 31, 2015, if the Company does not in fact purchase the Required Volume the Company will be obligated to pay the Price per Kilogram for the difference in kilograms between the Required Volume and the amount actually purchased. If Grace is unable to deliver the Required Volume by December 31, 2015, it will continue to deliver nicotinamide riboside chloride until it has delivered the Required Amount and the Company will pay for amounts delivered after December 31, 2015 within 60 days after they have been delivered. As of October 3, 2015, the Company had purchased approximately $1.0 million of the $6.1 million it is required to purchase pursuant to the agreement.

-16-

Table of Contents

Note 10. Related Party Transactions

On August 28, 2015, the Company entered into an Exclusive Supply Agreement (the “Supply Agreement”) with Healthspan Research, LLC (“Healthspan”). Under the terms of the Supply Agreement, Healthspan agreed to purchase NIAGEN® from the Company and the Company granted to Healthspan worldwide rights for resale of specific dietary supplements containing NIAGEN® in certain markets.

Pursuant to the terms of the Supply Agreement, in exchange for a 4% equity interest in Healthspan, the Company agreed to initially supply NIAGEN® to Healthspan free of charge and thereafter at a fixed price and, in exchange for an additional 5% equity interest in Healthspan, the Company will grant to Healthspan certain exclusive rights to resell NIAGEN® in certain direct response channels. Healthspan will pay the Company royalties on the cumulative worldwide net sales of its finished products containing NIAGEN®. The exclusivity rights will remain for so long as Healthspan meets certain minimum purchase requirements. In the event that, during the initial term, the Company terminates the exclusivity rights due to failure to meet the minimum purchase requirements or for any reason other than a material breach of the Supply Agreement by Healthspan, then the 5% equity interest shall be automatically redeemed for a purchase price of $1.00 effective upon the date of termination of the exclusivity rights.

In connection with the foregoing, also on August 28, 2015, the Company and Healthspan entered into an interest purchase agreement and limited liability company agreement pursuant to which the Company was issued 9% of the outstanding equity interests of Healthspan. Rob Fried, a director of the Company, is the manager of Healthspan and owns 91% of the outstanding equity interests of Healthspan. The Supply Agreement, interest purchase agreement and limited liability company agreement were unanimously approved by the independent directors of the Company.

As of October 3, 2015, the Company had not shipped any NIAGEN® to Healthspan and no accounting was done for the nine-month period ended on October 3, 2015.

Note 11. Subsequent Events

Subsequent to the nine-month period ended October 3, 2015, the Company entered into Securities Purchase Agreements with certain existing stockholders to raise $2,000,000 in a registered direct offering. Pursuant to the SPAs, the Company sold a total of 200,000 Units at a purchase price of $10.00 per Unit, with each Unit consisting of eight shares of the Company’s common stock and a warrant to purchase four shares of common stock with an exercise price of $1.50 and a term of 3 years. The offering was made pursuant to a prospectus supplement dated November 4, 2015 and an accompanying prospectus dated May 8, 2015 pursuant to the Company’s shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on May 8, 2015 and became effective on June 5, 2015 (File No. 333-203204). The prospectus supplement registered the shares of common stock issued in the offering and the common stock underlying the warrants.

-17-

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

GENERAL

This Quarterly Report on Form 10−Q (the “Form 10−Q”) contains “forward-looking statements,” as defined in Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company’s current expectations of the future results of its operations, performance and achievements. Forward-looking statements are covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company has tried, wherever possible, to identify these statements by using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends” and similar expressions. These statements reflect management’s current beliefs and are based on information now available to it. Accordingly, these statements are subject to certain risks, uncertainties and contingencies that could cause the Company’s actual results, performance or achievements in 2015 and beyond to differ materially from those expressed in, or implied by, such statements. Such statements, include, but are not limited to, statements contained in this Form 10-Q relating to our business, financial performance, business strategy, recently announced transactions and capital outlook. Important factors that could cause actual results to differ materially from those in the forward- looking statements include: a continued decline in general economic conditions nationally and internationally; decreased demand for our products and services; market acceptance of our products; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; the inability to raise capital to fund continuing operations; changes in government regulation; the ability to complete customer transactions, and other factors relating to our industry, our operations and results of operations and any businesses that may be acquired by us. Should one or more of these or other risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Additional risks, uncertainties, and other factors are set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ending January 3, 2015 and filed with the Commission on March 19, 2015 and in future reports the Company files with the Commission. Readers of this Form 10−Q should not place undue reliance on any forward-looking statements. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

You should read the following discussion and analysis of the financial condition and results of operations of the Company together with the financial statements and the related notes presented in Item 1 of this Form 10-Q.

Overview

The Company is a natural products company that leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to the Company’s ingredient technologies unit, the Company also has business units focused on natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting. As a result of the Company’s relationships with leading universities and research institutions, the Company is able to discover and license early stage, Intellectual Property-backed ingredient technologies. The Company then utilizes the Company’s in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. The Company’s ingredient portfolio is backed with clinical and scientific research, as well as extensive Intellectual Property protection.

The discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues, if any, and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

-18-

Table of Contents

As of October 3, 2015, the Company had approximately $4,709,000 cash and cash equivalents on hand as of October 3, 2015. Subsequent to the nine-month period ended October 3, 2015, the Company entered into Securities Purchase Agreements with certain existing stockholders, under which the Company raised $2,000,000 in a registered direct offering through the sale to such stockholders of an aggregate of 200,000 Units at a purchase price of $10.00 per Unit, with each Unit consisting of eight shares of the Company’s common stock and a warrant to purchase four shares of common stock with an exercise price of $1.50 and a term of 3 years.

With the capital raise described above, we anticipate that our current cash and cash equivalents on hand, and cash generated from operations will be sufficient to meet our projected operating plans through at least December 31, 2016. We may, however, seek additional capital prior to December 31, 2016, both to meet our projected operating plans after December 31, 2016 and/or to fund our longer term strategic objectives.

Additional capital may come from public and/or private stock or debt offerings, borrowings under lines of credit or other sources. These additional funds may not be available on favorable terms, or at all. Further, if we issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution and the new equity or debt securities we issue may have rights, preferences and privileges senior to those of our existing stockholders. In addition, if we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to our products or proprietary technologies, or to grant licenses on terms that are not favorable to us. If we cannot raise funds on acceptable terms, we may not be able to develop or enhance our products, obtain the required regulatory clearances or approvals, achieve long term strategic objectives, take advantage of future opportunities, or respond to competitive pressures or unanticipated customer requirements. Any of these events could adversely affect our ability to achieve our development and commercialization goals, which could have a material and adverse effect on our business, results of operations and financial condition. If we are unable to establish small to medium scale production capabilities through our own plant or though collaboration we may be unable to fulfill our customers’ requirements. This may cause a loss of future revenue streams as well as require us to look for third party vendors to provide these services. These vendors may not be available, or charge fees that prevent us from pricing competitively within our markets.

Some of our operations are subject to regulation by various state and federal agencies. In addition, we expect a significant increase in the regulation of our target markets. Dietary supplements are subject to FDA, FTC and U.S. Department of Agriculture regulations relating to composition, labeling and advertising claims. These regulations may in some cases, particularly with respect to those applicable to new ingredients, require a notification that must be submitted to the FDA along with evidence of safety. There are similar regulations related to food additives.

Results of Operations

Our net sales and net loss for the three- and nine-month periods ending on October 3, 2015 and September 27, 2014 were as follows:

	Three months ending						Nine months ending
	Oct. 3, 2015			Sept. 27, 2014			Oct. 3, 2015			Sept. 27, 2014

Net sales	$	6,287,000		$	4,140,000		$	17,650,000		$	11,070,000
Net loss		(4,000	)		(660,000	)		(1,344,000	)		(4,161,000	)

Basic and Diluted loss per common share	$	(0.00	)	$	(0.01	)	$	(0.01	)	$	(0.04	)

Over the next two years, we plan to continue to increase research and development efforts for our line of proprietary ingredients, subject to available financial resources.

-19-

Table of Contents

Net Sales

Net sales consist of gross sales less discounts and returns.

	Three months ending							Nine months ending
	Oct. 3, 2015		Sept. 27, 2014		Change			Oct. 3, 2015		Sept. 27, 2014		Change
Net sales:
Ingredients	$	4,147,000	$	2,031,000		104	%	$	10,239,000	$	4,889,000		109	%
Core standards and contract services		1,875,000		1,815,000		3	%		6,547,000		5,408,000		21	%
Scientific and regulatory consulting		265,000		294,000		-10	%		864,000		773,000		12	%

Total net sales	$	6,287,000	$	4,140,000		52	%	$	17,650,000	$	11,070,000		59	%

·	The increases in sales for the ingredients segment are due to increased sales throughout most of the ingredients we sell, including “NIAGEN®,” “PURENERGY®,” and “PTEROPURE®.”

·	The increases in sales for the core standards and contract services segment are primarily due to increased sales of analytical testing and contract services.

The sales for the scientific and regulatory consulting segment decreased 10% for the three-month period ended October 3, 2015, but increased 12% for the nine-month period ended October 3, 2015, in each case compared to the comparable periods in 2014. Fewer consulting projects for customers were completed during the three-month period ended October 3, 2015 as we focused more on completing internal projects.

Cost of Sales

Cost of sales include raw materials, labor, overhead, and delivery costs.

	Three months ending										Nine months ending
	Oct. 3, 2015					Sept. 27, 2014					Oct. 3, 2015					Sept. 27, 2014
	Amount		% of net sales			Amount		% of net sales			Amount		% of net sales			Amount		% of net sales
Cost of sales:
Ingredients	$	2,157,000		52	%	$	1,201,000		59	%	$	5,630,000		55	%	$	2,962,000		61	%
Core standards and contract services		1,533,000		82	%		1,239,000		68	%		4,743,000		72	%		3,729,000		69	%
Scientific and regulatory consulting		115,000		43	%		177,000		60	%		397,000		46	%		472,000		61	%

Total cost of sales	$	3,805,000		61	%	$	2,617,000		63	%	$	10,770,000		61	%	$	7,163,000		65	%

The cost of sales, as a percentage of net sales, decreased 2% and 4% for the three- and nine-month periods ended October 3, 2015, respectively, compared to the comparable periods in 2014.

·	The decreases in cost of sales, as a percentage of net sales, for the ingredients segment are largely due to the increased purchase volume, which enabled us to obtain lower prices from our suppliers as a result.

The cost of sales as a percentage of net sales for the core standards and contract services segment increased to 82% from 68% for the three-month period ended October 3, 2015 and increased to 72% from 69% for the nine-month period ended October 3, 2015. The increase in cost as a percentage of net sales is mainly due to increased costs in fine chemical reference standards as additional reserves were placed for the portion of the inventory that are considered slow-moving and obsolete. In addition, there was a one-time severance payment related to the termination of a certain employee during the three-month period ended October 3, 2015, which resulted in additional cost.

·	The percentage decreases in cost of sales for the scientific and regulatory consulting segment are largely due to higher utilizations of in-house consulting labor. Less work was subcontracted out to 3rd party consultants.

-20-

Table of Contents

Gross Profit

Gross profit is net sales less the cost of sales and is affected by a number of factors including product mix, competitive pricing and costs of products and services.

	Three months ending							Nine months ending
	Oct. 3, 2015		Sept. 27, 2014		Change			Oct. 3, 2015		Sept. 27, 2014		Change
Gross profit:
Ingredients	$	1,990,000	$	830,000		140	%	$	4,609,000	$	1,927,000		139	%
Core standards and contract services		342,000		576,000		-41	%		1,804,000		1,679,000		7	%
Scientific and regulatory consulting		150,000		117,000		28	%		467,000		301,000		55	%

Total gross profit	$	2,482,000	$	1,523,000		63	%	$	6,880,000	$	3,907,000		76	%

·	The increased gross profits for the ingredients segment are due to the increased sales throughout the ingredient portfolio we offer, as well as obtaining lower prices from our suppliers as a result of increased purchase volumes.

The decreased gross profit for the core standards and contract services segment for the three-month period ended October 3, 2015 is largely due to increased costs in fine chemical reference standards as additional reserves were placed for the portion of the inventory that are considered slow-moving and obsolete. In addition, the labor utilization was relatively low as the sales for analytical testing and contract services did not increase in proportion to the increase in fixed labor costs. Lastly, there was a one-time severance payment related to the termination of a certain employee which resulted in additional cost. The gross profit, however, increased for the nine-month period ended October 3, 2015, mainly due to increase in sales.

·	The increased gross profits for the scientific and regulatory consulting segment are largely due to higher utilizations of in-house consulting labor.

Operating Expenses-Sales and Marketing

Sales and Marketing Expenses consist of salaries, advertising and marketing expenses.

	Three months ending							Nine months ending
	Oct. 3, 2015		Sept. 27, 2014		Change			Oct. 3, 2015		Sept. 27, 2014		Change
Sales and marketing expenses:
Ingredients	$	260,000	$	243,000		7	%	$	833,000	$	793,000		5	%
Core standards and contract services		288,000		260,000		11	%		935,000		695,000		35	%
Scientific and regulatory consulting		3,000		16,000		-81	%		8,000		67,000		-88	%

Total sales and marketing expenses	$	551,000	$	519,000		6	%	$	1,776,000	$	1,555,000		14	%

-21-

Table of Contents

·	For the ingredients segment, we were able to maintain sales and marketing expenses at a similar level of the comparable periods in 2014 despite the significant increases in sales. We do anticipate increased expenses going forward as we increase marketing efforts for our proprietary ingredients.

·	For the core standards and contract services segment, the increases are largely due to hiring additional sales and marketing staff and making certain operational changes.

·	For the scientific and regulatory consulting segment, we had very little sales and marketing expenses compared to comparable periods in 2014.

Operating Expenses-General and Administrative

General and Administrative Expenses consist of research and development, general company administration, IT, accounting and executive management.

	Three months ending							Nine months ending
	Oct. 3, 2015		Sept. 27, 2014		Change			Oct. 3, 2015		Sept. 27, 2014		Change

General and administrative	$	1,754,000	$	1,652,000		6	%	$	6,017,000	$	6,458,000		-7	%

General and Administrative Expenses increased 6% for the three-month period ended October 3, 2015, however, decreased 7% for the nine-month period ended October 3, 2015, compared to the comparable periods in 2014. One of the factors that contributed to the decreases in general and administrative expense for the nine-month period was a decrease in share-based compensation. For the nine-month period ended October 3, 2015, our share-based compensation decreased to approximately $1,657,000, compared to approximately $2,468,000 for the comparable period in 2014.

In 2014, we had higher share-based compensation expenses as we awarded an aggregate of 1,090,000 shares of restricted stock to the Company’s officers and members of the board of directors. The fair values of these restricted stock awards were approximately $1,537,000 in aggregate, which were expensed over a period of six months from January 2, 2014 to July 1, 2014.

Non-operating income- Interest Income

Interest income consists of interest earned on money market accounts. Interest income for the nine-month period ended October 3, 2015 was approximately $2,000, a slight increase compared to approximately $1,000 for the nine-month period ended September 27, 2014.

Non-operating Expenses- Interest Expense

Interest expense consists of interest on loan payable and capital leases.

	Three months ending							Nine months ending
	Oct. 3, 2015		Sept. 27, 2014		Change			Oct. 3, 2015		Sept. 27, 2014		Change

Interest expense	$	182,000	$	12,000		1417	%	$	434,000	$	34,000		1176	%

The increases in interest expense were mainly related to the Term Loan Agreement dated September 29, 2014, between the Company and Hercules Technology II, L.P, which the Company drew down first $2.5 million on September 29, 2014 and second $2.5 million on June 18, 2015. For more information on this term loan, please refer to Note 6 of Financial Statements appearing in Part I of this report.

-22-

Table of Contents

Depreciation and Amortization

Depreciation expense for the nine-month period ended October 3, 2015, was approximately $210,000 as compared to $162,000 for the nine-month period ended September 27, 2014. We depreciate our assets on a straight-line basis, based on the estimated useful lives of the respective assets. Amortization expense of intangible assets for the nine-month period ended October 3, 2015, was approximately $32,000 as compared to $25,000 for the nine-month period ended September 27, 2014. We amortize intangible assets using a straight-line method over 10 years.

Liquidity and Capital Resources

From inception and through October 3, 2015, we have incurred aggregate losses of approximately $41 million. These losses are primarily due to expenses associated with the development and expansion of our operations. These operations have been financed through capital contributions, the issuance of common stock and warrants through private placements, and the issuance of debt.

Our board of directors periodically reviews our capital requirements in light of our proposed business plan. Our future capital requirements will remain dependent upon a variety of factors, including cash flow from operations, the ability to increase sales, increasing our gross profits from current levels, reducing selling and administrative expenses as a percentage of net sales, continued development of customer relationships, and our ability to market our new products successfully. However, based on our results from operations, we may determine that we need additional financing to implement our business plan. There can be no assurance that any such financing will be available on terms favorable to us or at all. Without adequate financing we may have to further delay or terminate product and service expansion and curtail certain selling, general and administrative expenses. Any inability to raise additional financing would have a material adverse effect on us.

The Company had approximately $4,709,000 cash and cash equivalents on hand as of October 3, 2015. Subsequent to the nine-month period ended October 3, 2015, the Company entered into Securities Purchase Agreements with certain existing stockholders under which the Company raised $2,000,000 in a registered direct offering through the sale to such stockholders of an aggregate of 200,000 Units at a purchase price of $10.00 per Unit, with each Unit consisting of eight shares of the Company’s common stock and a warrant to purchase four shares of common stock with an exercise price of $1.50 and a term of 3 years.

With the capital raise described above, we anticipate that our current cash and cash equivalents on hand, and cash generated from will be sufficient to meet our projected operating plans through at least December 31, 2016. We may, however, seek additional capital prior to December 31, 2016, both to meet our projected operating plans through and after December 31, 2016 and to fund our longer term strategic objectives. To the extent we are unable to raise additional cash or generate sufficient revenue to meet our projected operating plans prior to December 31, 2016, we will revise our projected operating plans accordingly.

Net cash used in operating activities

Net cash used in operating activities for the nine months ended October 3, 2015 was approximately $1,258,000 as compared to approximately $2,335,000 for the nine months ended September 27, 2014. Along with the net loss, increases in trade receivables and inventories were the largest uses of cash during the nine-month period ended October 3, 2015. Net cash used in operating activities for the nine months ended September 27, 2014 largely reflects an increase in trade receivables and a decrease in customer deposits along with the net loss.

We expect our operating cash flows to fluctuate significantly in future periods as a result of fluctuations in our operating results, shipment timetables, accounts receivable collections, inventory management, and the timing of our payments, among other factors.

-23-

Table of Contents

Net cash provided by (used in) investing activities

Net cash used in investing activities was approximately $350,000 for the nine months ended October 3, 2015, compared to approximately $950,000 provided by for the nine months ended September 27, 2014. Net cash used in investing activities for the nine months ended October 3, 2015 mainly consisted of purchases of leasehold improvements and equipment and intangible assets. Net cash provided by investing activities for the nine months ended September 27, 2014 mainly consisted of proceeds received from the assignment of the Senior Note issued by NeutriSci to an unrelated third party. NeutriSci originally issued the Senior Note to the Company as a part of the consideration for the purchase of the BluScience product line.

Net cash provided by financing activities

Net cash provided by financing activities was approximately $2,352,000 for the nine months ended October 3, 2015, compared to approximately $327,000 for the nine months ended September 27, 2014. Net cash provided by financing activities for the nine months ended October 3, 2015 mainly consisted of proceeds from the 2nd draw of the term loan we entered into with Hercules Technology II, L.P. Net cash provided by financing activities for the nine months ended September 27, 2014 mainly consisted of proceeds from exercise of stock options, offset by principal payments on capital leases.

Dividend policy

We have not declared or paid any dividends on our common stock. We presently intend to retain earnings for use in our operations and to finance our business. Any change in our dividend policy is within the discretion of our Board of Directors and will depend, among other things, on our earnings, debt service and capital requirements, restrictions in financing agreements, if any, business conditions, legal restrictions and other factors that our Board of Directors deems relevant.

Off-Balance Sheet Arrangements

During the nine months ended October 3, 2015, we had no significant off-balance sheet arrangements other than ordinary operating leases as disclosed in the “Financial Statements and Supplementary Data” section of the Company’s Annual Report on Form 10-K for the year ending January 3, 2015 and filed with the Commission on March 19, 2015.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk

The Company had an outstanding loan payable of $5.0 million at October 3, 2015. Interest is payable monthly at the greater of either (i) 9.35% plus the prime rate as reported in The Wall Street Journal (the “Prime Rate”) minus 3.25%, or (ii) 9.35%. If the Prime Rate rises, the Company will incur more interest expenses. The loan is repayable in installments through April 1, 2018, following an initial interest-only period until March 31, 2016, provided however that if the Company’s consolidated revenue is equal to or greater than $11.5 million for the six months ending December 31, 2015, then the interest-only period shall be extended to June 30, 2016.

Our capital lease obligations bear interest at a fixed rate and therefore have no exposure to changes in interest rates.

The Company’s cash consists of short term, high liquid investments in money market funds managed by banks. Due to the short-term duration of our investment portfolio and the relatively low risk profile of our investments, a sudden change in interest rates would not have a material effect on either the fair market value of our portfolio, or our operating results or cash flows.

-24-

Table of Contents

Foreign Currency Risk

All of our long-lived assets are located within the United States and we do not hold any foreign currency denominated financial instruments.

Effects of Inflation

We do not believe that inflation and changing prices during the nine months ended October 3, 2015 and September 27, 2014 had a significant impact on our results of operations.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a – 15(e) and 15d – 15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this quarterly report. They have concluded that, based on such evaluation, our disclosure controls and procedures were effective as of October 3, 2015.

Changes in Internal Control over Financial Reporting

There was no change in internal control over financial reporting (as defined in Rule 13a−15(f) promulgated under the Securities Exchange Act of 1934) that occurred during the Company’s third fiscal quarter that has materially affected or is reasonably likely to materially affect the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are not involved in any legal proceedings which management believes may have a material adverse effect on our business, financial condition, operations, cash flows, or prospects. The Company from time to time is involved in legal proceedings in the ordinary course of our business, which can include employment claims, product claim, patent infringement, etc. We do not believe that any of these claims and proceedings against us as they arise are likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

-25-

Table of Contents

ITEM 6. EXHIBITS

Exhibit No.		Description of Exhibits
10.1		Exclusive Supply Agreement, effective as of August 27, 2015 between Healthspan Research, LLC. and ChromaDex, Inc. (1)
10.2		Limited Liability Company Agreement, effective as of August 27, 2015 between Healthspan Research LLC and ChromaDex, Inc. (1)
10.3		Interest Purchase Agreement, effective as of August 27, 2015 between Healthspan Research LLC and ChromaDex, Inc. (1)
10.4		Take or Pay Purchase Agreement for nicotinamide riboside chloride, effective as of September 21, 2015, between W.R. Grace & Co. Conn. And ChromaDex, Inc. (1)
10.5		Supply Agreement, effective as of August 28, 2015 and First Addendum to Supply Agreement, effective as of September 30, 2015 between Nectar7 LLC and ChromaDex, Inc. (1)
31.1		Certification of the Chief Executive Officer pursuant to §240.13a−14 or §240.15d−14 of the Securities Exchange Act of 1934, as amended
31.2		Certification of the Chief Financial Officer pursuant to §240.13a−14 or §240.15d−14 of the Securities Exchange Act of 1934, as amended
32.1		Certification pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002)

(1)	A redacted version of this Exhibit is filed herewith. An un-redacted version of this Exhibit has been separately filed with the Commission pursuant to an application for confidential treatment. The confidential portions of the Exhibit have been omitted and are marked by an asterisk.

-26-

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 12, 2015

ChromaDex Corporation

(Registrant)

/s/ THOMAS C. VARVARO

Thomas C. Varvaro

Duly Authorized Officer and Chief Financial Officer

-27-

Niagen Bioscience - 10-Q quarterly report FY2015 Q3

What is the market capitalization of a company?

DISCLAIMER

Contact

Links